We are developing transformative treatments for patients with neurological and neurodevelopmental disorders through breakthrough science built on proven research.

Marvel Biosciences is a Canadian biotechnology company developing breakthrough therapies for complex neurological and neurodevelopmental disorders, including autism spectrum disorder, Rett syndrome, and Fragile X syndrome.

Our lead program target, MB-204, has demonstrated preclinical efficacy across these high-need indications and is advancing toward first-in-human studies.

Our approach is to reinvent existing molecules through precise chemical innovation to create safer, faster, and more effective treatments. This brings reliability of established mechanisms with the novelty of next-generation chemistry, accelerating development while reducing risk.

With completed cGMP synthesis and toxicology studies, Marvel Biosciences is advancing toward the clinic to change how neurological diseases are treated.

 Our drug assets are strategically developed to target large and growing markets, addressing significant unmet medical needs across diverse patient populations.

Marvel Biosciences is specifically targeting